Di­ag­nos­tic champ Roche buys its way in­to the RET ti­tle fight with Eli Lil­ly, pay­ing $775M in cash to Blue­print

When Roche spelled out its orig­i­nal $1 bil­lion deal — $45 mil­lion of that up­front — with Blue­print to dis­cov­er tar­get­ed ther­a­pies against im­munok­i­nas­es, the biotech part­ner …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER